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Abstract
Background: Theoretical links between seasonal lack of sunlight, hypovitaminosis D and
excess cardiovascular disease and death prompted our adding novel to conventional co-
hort analyses.
Methods: We tested three postulates on 13 224 Scottish Heart Health Extended Cohort
participants, assayed for 25-hydroxyvitamin D (25OHD) and followed for 22 years.
(i) Endpoints enumerated by month of occurrence mirror annual seasonal oscillation in
25OHD. (ii) Endpoint seasonality is increased in people with below median 25OHD.
(iii) Low 25OHD predicts endpoints independently of major risk factors.
Results: Baseline median 25OHD level was 36.4 (other quartiles 26.7, 51.7) nmol/l. The
March trough was half the August peak, both well after seasonal solstices. (i) There was no
demonstrable monthly variation in First Cardiovascular Event (n¼3307). Peaks and
troughs for All Death and Cardiovascular Death (n¼ 2987, 1350) were near the solstices,
earlier than extremes of 25OHD. (ii) Endpoint variability showed no difference between
those above and below median 25OHD. (iii) Cox model hazard ratios (HR), by decreasing
25OHD, increasedmodestly and nonspecifically for all endpoints examined, with no thresh-
old, the gradients diminishing by~ 60% following multiple adjustment. For Cardiovascular
Disease, HR, by 20 (SD) nmol/l decrease, ¼ 1.224 (1.175, 1.275) adjusted for age and sex;
additionally adjusted for family history, deprivation index, smoking, systolic blood pres-
sure, total and HDL cholesterol, ¼ 1.093 (1.048, 1.139); All Deaths¼1.238 (1.048, 1.139) and
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1.098 (1.050, 1.149). 25OHD made no independent contribution to cardiovascular discrimin-
ation and reclassification.
Conclusions: Our analyses challenge vitamin D’s alleged role as major prime mover in
cardiovascular disease and mortality.
Key words: : Vitamin D, causality, seasonality, cardiovascular disease, mortality, cohort study
Introduction
Debate as to whether low population levels of vitamin D
cause mass disease is stimulating large cohort studies, meta-
analyses and trials,1–6 and studies of mendelian randomiza-
tion.7 Earlier research produced inconclusive results8,9 despite
rapid increases in clinical testing and prescribing.10,11
Meanwhile an existing natural experiment remains under-
investigated. Population vitamin D levels are driven by expos-
ure to sunlight.12,13 In 1981, Scragg hypothesized that excess
and winter peaks in cardiovascular disease and death in tem-
perate countries were caused by hypovitaminosis D (analo-
gous to childhood rickets a century earlier, see Figure 1).14
Now embedded in popular medical culture, this seasonality
hypothesis warrants critical testing, both in its own right and
to pursue this debate along a novel perspective.
Midwinter daylight hours in Edinburgh are 39% of mid-
summer (contrast with 61% in New York and Madrid).
The midwinter sun is also low in the sky, and there is a
gross seasonal decline in ultraviolet radiation. After deriv-
ing three postulates from the seasonality hypothesis, we
tested them on a Scottish cohort with long follow-up,15
examining Bradford Hill criteria for causality between vita-
min D, cardiovascular disease and mortality–specificity,
temporality, strength of association and gradient.16
Methods
Rationale
Participants in the Scottish Heart Health Extended Cohort
(SHHEC)15 were recruited over much of 7 years, so
Key Messages
• Winter excess of cardiovascular disease and death is attributed to hypovitaminosis D through lack of sunlight.
• We added seasonality to a conventional follow-up study of a Scottish cohort.
• Despite two-to-one, August-to-March, change in population serum 25-hydroxyvitamin D (25OHD), there was no sea-
sonal change in incident cardiovascular disease.
• Peaks in deaths appeared early in winter, therefore out-of-phase.
• There was no disproportionate seasonal susceptibility in people with low 25OHD.
• 25OHD was a modest predictor of endpoints, largely confounded by other risk factors, without an independent pre-
dictive effect for cardiovascular disease.
• Our results challenge vitamin D’s alleged seasonal and causal role.
Figure 1. Childhood rickets from hypovitaminosis D, especially
prevalent in Scotland in the early 1900s. (Wellcome Library, London).
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archived recruitment serum could be used subsequently to
show the annual cycle in vitamin D, averaged for each of
the 12 calendar months, measured as 25-hydroxyvitamin
D (25OHD). First cardiovascular events and deaths during
follow-up were also cumulated to the 12 calendar months
of occurrence to record seasonal variation. Because low
vitamin D levels occur in winter and higher levels in sum-
mer, the bulk of readings swinging up and down en masse,
‘raw’ recruitment readings (25OHDraw) were modified by
seasonal adjustment (25OHDadj). This defined the esti-
mated ranking of vitamin D status within the cohort, re-
gardless of season. It was used to divide the population in
half for one analysis, and in descending fifths for another.
Postulates
Through the above rationale we developed three ‘Dundee
Postulates’ for testing the seasonality hypothesis (see Box 1).
Scottish Heart Health Extended Cohort
This report comes from the Scottish Heart Health Extended
Cohort (SHHEC),15 the MORGAM Biomarker study
(MOnica, Risk, Genetics, Archiving and Monograph) and
BiomarCaRE (Biomarkers for Cardiovascular Risk
Assessment in Europe).17–19 SHHEC combines men and
women of the Scottish Heart Health Study (SHHS)l5 aged
40–59 years, recruited across 23 districts of Scotland in
1984–87,with those of Scottish MONICA20 aged 25–64
years from Edinburgh and North Glasgow 1986 and North
Glasgow 1989, 1992 (–74 years) and 1995. With ethical
committee approval, participants completed questionnaires,
attended recruitment survey clinics, gave blood and con-
sented to follow-up of their medical records. Each of the 23
SHHS districts was visited twice in different seasons,
whereas the North Glasgow MONICA surveys involved
four independent population samples in the same seasons at
3-year intervals. For both studies, general practitioners were
recruited randomly first, and their patient lists were then
subjected to second-stage random sampling.21
Previously diagnosed cardiovascular disease was identi-
fied by self-report and hospital discharge diagnoses: any
coronary heart disease; cerebrovascular disease, including
transient ischaemic attacks; heart failure; and peripheral
arterial disease. Mortality and hospital inpatient episodes
were followed by record linkage through 2009.22
Cardiovascular disease morbidity was first diagnosis as
above; mortality was any certified cardiovascular cause.
Primary endpoints were First Cardiovascular Event, All
Death and Cardiovascular Death. Secondary endpoints
were Coronary Heart Disease, Cerebrovascular Disease,
Non-cardiovascular Death and Cancer Death. The same
SHHEC database followed through 2005 was used previ-
ously to derive the ASSIGN cardiovascular risk score.23
Laboratory procedures
After venepuncture, blood was left to coagulate up to 4 h.
Separated serum was stored at 4C pending laboratory testing
1–3 days later. Aliquots were biobanked long-term at -40C24
and assayed for 25OHD in the MORGAM/BiomarCaRE bio-
marker laboratory as kits became available in 2009 and 2011.
The ARCHITECT system (Abbott Laboratories) uses chemi-
luminescent microparticle immunoassay; the intra-assay coef-
ficient of variation (CoV) was 5.0–9.5% and inter-assay CoV
1.4–8.7%. The assay is highly sensitive to natural 25OHD3,
less so to synthetic 25OHD2.
11,25
Statistical methods
The main test of the correspondence of seasonality between
25OHDraw and endpoint events (Postulate 1) was an ecolo-
gical analysis comparing their monthly patterns. To test for
increased susceptibility in winter in the ‘LowD people’ vs
‘HighD’ halves of 25OHDadj (Postulate 2), their endpoint
events were apportioned separately between ‘Low-D’ and
‘High-D’ seasons and the resulting two-by-two tables tested
for heterogeneity using the chi square statistic. Cox propor-
tional hazard analyses for Postulate 3 included endpoints
after recruitment, regardless of season. Hazard ratios were
adjusted for age and sex, then multiply adjusted for ASSIGN
cardiovascular risk factors.23 The cohort was divided into
fifths in descending order of 25OHDadj. The baseline hazard
ratio of 10 was ascribed to the first fifth (100–80th centile).
For First Cardiovascular Event, discrimination, meas-
ured using a c-statistic, differences in discrimination and
the net reclassification improvement (NRI),(with thresh-
olds of 10% and 20% 10-year risk) on adding 25OHDadj
Box 1. Dundee Postulates based on the seasonality
hypothesis
Seasonality Postulate 1. Endpoints, (First
Cardiovascular Event, All Death and Cardiovascular
Death), enumerated by calendar month of occur-
rence, inversely reflect seasonal fluctuation in recruit-
ment 25-hydroxyvitamin D: 25OHDraw.
Seasonality Postulate 2. This endpoint variability is
accentuated in those with low vs high seasonally ad-
justed 25OHDadj, who experience more hypovita-
minosis D in winter.
Postulate 3. Low vs high 25OHDadj is predictive of
endpoints, independently of other risk factors.
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to the prognostic model, over and above ASSIGN vari-
ables, were computed allowing for censoring.26–28
Results
Population numbers
Cross-sectional analyses included 13 224 participants
assayed for 25OHDraw. Follow-up studies excluded 498
below age 30 and 1098 with previous cardiovascular dis-
ease. For Seasonality Postulates 1 and 2, events were fol-
lowed for whole calendar years so 31 victims afflicted in
the calendar year of recruitment were excluded, leaving
11 597, whereas for the Cox proportional hazards analyses
(Postulate 3) the 31 were included, making 11 628.
Recruitment 25OHDraw
Seasonal change was as anticipated. The averaged
25OHDraw by calendar month of recruitment was twice as
high in August (maximum) as in March (minimum), the
extremes occurring weeks after the solstices. Female values
were lower than in men, with a smaller summer rise
(Table 1). Differences were highly significant. After adjust-
ment for seasonality, there was little variation between
months: 25OHDadj. Differing monthly totals reflect cumu-
lative recruitment activity.
Follow-up
First Cardiovascular Event, All Death and Cardiovascular
Death were enumerated by calendar month of occurrence
(Table 2, columns b–d). Resulting endpoint totals were split
between the two sub-populations, LowD people / HighD
people, either side of the median 25OHDadj of 38.2 nmol/l
(Table 2, columns e–j). Results are unadjusted for length of
month.
Seasonal pattern of 25OHDraw vs occurrence of
endpoints (Postulate 1)
The raw monthly totals of endpoints from Table 2 were
adjusted to a monthly duration of 30.44 days. Numbers
were then normalized to percentage of the corresponding
monthly mean, as was also done for 25OHDraw (see
Supplement Table W1, available as Supplementary data
at IJE online). Results are displayed as radar plots in
Figure 2, contrasting the seasonal pattern in 25OHDraw
and the three primary endpoints.
Circular plots in colour are shown against 100% in
black. Calendar months in which deviation exceeds the
Table 1. Mean monthly 25-hydroxyvitamin D: 25OHDraw (standard deviation) by calendar month of recruitment. Then after ad-
justment: 25OHDadj. 13 224 participants in the Scottish Heart Health Extended Cohort (SHHEC) with archived serum
Month (rank) Number Men Women All All
25OHDraw 25OHDraw 25OHDraw 25OHDadj
nmol/l nmol/l nmol/l nmol/l
n¼6539 n¼6685 n¼13 224 n¼13 224
January (3)a 680 33.7 (15.6) 30.9 (17.1) 32.2 (16.5) 41.6 (21.2)
February (2)a 689 32.3 (13.3) 29.3 (12.7) 30.6 (13.1) 40.6 (17.3)
March (1)a 1266 30.1 (12.3) 29.7 (13.0) 29.9 (12.6) 41.2 (17.4)
April (4)a 1448 34.3 (17.0) 31.6 (15.0) 32.9 (16.1) 41.6 (20.3)
May (5)a 1585 37.9 (15.9) 33.9 (15.0) 36.0 (15.6) 41.3 (17.9)
June (9)b 1543 47.0 (22.1) 40.9 (19.5) 43.7 (21.0) 43.2 (20.7)
July (11)b 900 60.5 (23.2) 53.1 (20.0) 56.8 (22.0) 40.5 (15.7)
August (12)b 1344 64.2 (27.0) 53.1 (22.1) 58.6 (25.3) 41.4 (17.8)
September (10)b 1060 58.1 (26.1) 51.0 (24.6) 54.6 (25.6) 41.8 (19.6)
October (8)b 1240 45.3 (18.4) 39.9 (18.2) 42.4 (18.5) 41.0 (17.9)
November (7)b 971 39.9 (16.8) 36.6 (16.6) 38.3 (16.8) 41.3 (18.1)
December (6)a 498 38.8 (18.7) 33.7 (16.7) 36.3 (17.9) 41.5 (20.5)
All 13224 44.0 (22.6) 39.0 (19.9) 41.5 (21.4) 41.5 (18.7)
Standard error of the mean 0.28 0.24 0.19 0.16
March vs August
P<0.0001
A general linear model was fitted to estimate the excess log 25OHDraw each month compared with January, adjusting for age, sex and their interaction. The ex-
cess was subtracted so that each month had standardized ‘January’ levels; finally all values were reweighted to achieve the observed overall mean, yielding
25OHDadj. The ranking of months (low to high) is based on mean monthly values for sexes combined of 25OHDraw.
aLow-D season.
bHigh-D season.
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Table 2. Endpoint numbers by calendar month of follow-up: overall totals, and then by sub-populations of LowD people and
HighD people separated at the median (38.2 nmol/l) of 25OHDadj (n¼11 597 for sexes combined, LowD people n¼5799, HighD
people n¼ 5798)
a b c d e f g h i j
Population All All All LowD people HighD people LowD people HighD people LowD people HighD people
endpoint First CV All Death CV Death First CV First CV All Death All Death CV Death CV Death
month Event Event Event
January 281 277 140 148 133 161 116 84 56
February 250 217 93 138 112 121 96 55 38
March 270 236 112 136 134 115 121 59 53
April 295 247 114 174 121 137 110 66 48
May 271 221 100 146 125 119 102 61 39
June 287 216 96 152 135 123 93 54 42
July 285 234 104 165 120 143 91 63 41
August 253 243 115 153 100 139 104 63 52
September 276 224 109 142 134 114 110 55 54
October 296 249 122 143 153 131 118 71 51
November 267 257 122 152 115 140 117 73 49
December 276 276 123 148 128 164 112 75 48
Total 3307 2897 1350 1797 1510 1607 1290 779 571
Mean 2756 2414 1125 1498 1258 1339 1075 649 476
Numbers are not corrected for length of month, but see Supplementary Table W1 (available as Supplementary data at IJE online). For ranking of months and
Low-D/ High-D season see Table 1.
First CV Event, First Cardiovascular Event; All Death, deaths from all causes; CV Death, death from cardiovascular causes.
a–j are for convenience of reference in the main text.
A 25-hydroxyvitamin D (25OHDraw) N=13 224 B First Cardiovascular Event N=3307
C All Death N=2897 D Cardiovascular Death N=1350
Jan
Feb*
Mar**
Apr
May
Jun
Jul*
Aug**
Sep*
Oct
Nov
Dec
Jan
Feb
Mar
Apr**
May
Jun*
Jul
Aug**
Sep
Oct*
Nov
Dec
Jan**
Feb
Mar
Apr
May**
Jun*
Jul
Aug
Sep
Oct
Nov*
Dec**
Jan**
Feb*
Mar
Apr
May*
Jun**
Jul
Aug
Sep
Oct
Nov
Dec
Figure 2. Radar plots from the SHHEC population of monthly variation in: A, recruitment 25-hydroxyvitamin D (25OHDraw); B, First Cardiovascular
Event; C, All Death; and D, Cardiovascular Death, testing Seasonality Postulate 1. Sexes combined, n¼ 11 597, 22-year follow-up. Mean for all months
(100%) shown in black. (Plotted from Supplementary Table W1, available as Supplementary data at IJE online).
*Outside coefficient of variation, **Highest and lowest monthly values (see text).
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coefficient of variation (CoV) are asterisked; highest and
lowest months have double asterisks.
Monthly values of 25OHDraw (Figure 2A) show a cyc-
lical annual doubling and halving, peak and trough each
lasting several months, centred on late summer (August) and
late winter (March), respectively. The seasonality hypoth-
esis, Postulate 1, predicts the converse pattern for endpoints.
For First Cardiovascular Event (Figure 2B), the plot
shows no deviation from circularity (P¼084). Between-
months CoV is small at 5.0%; no deviation persists. Huge
seasonal changes in 25OHDraw appear to leave the monthly
incidence of First Cardiovascular Events unperturbed.
Patterns for All Death (Figure 2C) and Cardiovascular
Death (Figure 2D) are ovoid and consistent with seasonal
variation in deaths in national statistics. CoVs are larger
than for First Cardiovascular Events at 7.8% and 10.7%.
For both, the peak is in early winter; the trough in early sum-
mer. With smaller numbers, Cardiovascular Death appears
more subject to random deviation. For neither fatal end-
point do February or March plots, the nadir in 25OHDraw,
show the peak predicted by the seasonality hypothesis.14
The reciprocals of the monthly vitamin D values
(Supplement Table W1, available as Supplementary data at
IJE online) are 127% in February and 130% in March, but
no endpoint value exceeds 100%.
In contrast to 25OHDraw there is no seasonal pattern
for First Cardiovascular Event. What there is for All Death
and Cardiovascular Death precedes rather than follows the
late seasonal swings in 25OHDraw, failing Bradford Hill’s
criterion of temporality.16
Increased Low-D season susceptibility to
endpoints in those with low 25OHDadj (Postulate 2)
The null hypothesis for Postulate 2 involved testing for het-
erogeneity in endpoint occurrences. The cohort is split in
half at the median 25OHDadj value of 38.2 nmol/l into
LowD people and HighD people and the year into two 6-
month periods, Low-D season and High-D season, at the
39.3 nmol/l monthly median for 25OHDraw. After the low-
est 6 months against the highest, this was repeated for the
lowest vs highest four, and then lowest three by highest,
identifiable in Table 1. The seasons were not conventional
summer and winter but reflected the delayed response of
blood levels of 25OHDraw to seasonal sunlight. Aggregate
endpoint totals were sums of appropriate monthly num-
bers, see Table 2, columns e–j.
The results in Table 3 show no evidence of heterogen-
eity by season in endpoints between LowD and HighD
sub-populations. There is no increased susceptibility by
season in the former when tested on a six-by-six, four-by-
four or three-by-three basis. The second seasonality postu-
late is thus not supported in the SHHEC data.
Further analysis by rearrangement of two-by-two re-
sults is shown in Supplement Table W2 (available as
Supplementary data at IJE online). The Low-D season
overall does not show excess of First Cardiovascular
Events compared with High-D, but LowD people do have
more endpoint events than HighD people. The latter find-
ing is further explored in population fifths, using the Cox
proportional hazards model.
Table 3. Testing the null hypothesis for Dundee Seasonality Postulate 2 (greater seasonal susceptibility in LowD people) using
22 tables. Endpoints are partitioned by LowD people/HighD people at risk, and by Low-D season/High-D season of occur-
rence. Comparisons are of lowest and highest months for 25OHDraw, 6 months vs 6, 4 vs 4 and 3 vs 3 (see Table 1)
High-D vs
Low-D months
compared
Endpoint
numbers in
LowD people,
Low-D season
Endpoint
numbers in
LowD people,
High-D season
Endpoint
numbers in
HighD people,
Low-D season
Endpoint
numbers in
HighD people,
High-D season
chi square for
two-by-two table
P-value
(Yates)
n¼5799 n¼5799 n¼5798 n¼5798
First CV Event 6 vs 6 890 907 753 757 003 086
4 vs 4 596 612 500 489 0.28 0.60
3 vs 3 422 460 379 354 2.23 0.14
All Death 6 vs 6 817 790 657 633 000 100
4 vs 4 534 519 443 398 0.65 0.42
3 vs 3 397 396 333 305 0.56 0.45
CV Death 6 vs 6 400 379 282 289 043 051
4 vs 4 264 235 195 189 0.31 0.58
3 vs 3 198 181 147 147 0.25 0.62
Half-populations and half-years are almost identical in size. Endpoints from each population are being compared in two different time periods, so there is no
need to adjust for other factors. Correction for trivial differences both in numbers at risk and in cumulated numbers of days in comparison months had no effect
on chi square or P-values. Event numbers from Table 2. Further ratios explored in Supplement Table W2 (available as Supplementary data at IJE online).
Numbers are not corrected for length of month–but see Supplementary Table W1 (available as Supplementary data at IJE online). For ranking of months and
Low-D/ High-D season see Table 1.
International Journal of Epidemiology, 2015, Vol. 44, No. 5 1607
 at U
niversity of D
undee on M
ay 7, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
Cox proportional hazards by declining fifths of
25OHDadj (testing Postulate 3)
Table 4 shows the Cox proportional hazards model for pri-
mary endpoints, sexes combined and separately. Results
are by declining fifths of 25OHDadj, corrected for age and
sex, and then multiply adjusted (ma) for factors in the
ASSIGN score: age, sex, family history of coronary heart
disease, Scottish Index of Multiple Deprivation, tobacco
smoking dose, total cholesterol and high-density lipopro-
tein (HDL) cholesterol. Note that BMI (body mass index)
did not contribute significantly to the ASSIGN score, nor
did adding it in here.22 Ranges and mean values by
fifths for the sexes together and separately for 25OHDadj
are shown in Supplement Table W3 (available as
Supplementary data at IJE online).
There was some interaction by sex, significant for car-
diovascular deaths. The gradient of risk for women is shal-
lower than for men despite lower 25OHDadj values. The
modest increase in risk, in results adjusted for age and sex
alone, is attenuated by 60% after multiple adjustment,
losing statistical significance in women despite good
numbers. There was no evidence of a threshold, confirmed
by spline analyses (not shown). There was no increase in
risk associated with the highest 25OHDadj values (see
Supplement Table W4, available as Supplementary data at
IJE online). Linearity was thus modelled by analyses of
hazard ratios for a 20-nmol/l decrease (HRD20) in
25OHDadj (the standard deviation was 18.7 nmol/l). Very
similar hazard ratios for secondary endpoints (see
Supplement Table W5, available as Supplementary data at
IJE online) suggest lack of specificity in the apparent vita-
min D effect. These effects were, again, strongly attenuated
following multiple adjustment.
Most ASSIGN risk factors showed a significant linear re-
lationship with 25OHDadj. The ASSIGN score for cardio-
vascular risk was 25% higher in the final fifth of 25OHDadj
than in the first (see Supplement Table W6, available as
Supplementary data at IJE online), consistent with the im-
pact of ASSIGN factors in multiple adjustment.
In analyses of discrimination and net reclassification im-
provement for First Cardiovascular Event, sexes combined
and separately, changes in the c statistic and the NRI were
Table 4. Hazard ratios for primary endpoints, Cox proportional hazards model by fifths of descending 25OHDadj values, and by
20-nmol/l change (HRD20), age and sex adjusted; and then after multiple adjustment (ma) for ASSIGN variables, sexes com-
bined and separately.a All n¼11 628, men n¼5658, women n¼ 5970
Fifths 2 3 4 5 95% CL for 5 HRD20 95% CL for HRD20
Allb Events / At risk 2327 2323 2325 2326
First CV Event 3332 1.26 1.48 1.59 1.70 1.52,1.90 1.224 1.175,1.275
ma 1.13 1.27 1.24 1.25 1.11,1.40 1.093 1.048,1.139
All death 2928 1.25 1.40 1.65 1.67 1.48,1.89 1.238 1.185,1.294
ma 1.13 1.17 1.28 1.22 1.08,1.39 1.098 1.050,1.149
CV Death 1368 1.48 1.86 2.11 2.21 1.83,2.66 1.363 1.275,1.458
ma 1.27 1.51 1.55 1.48 1.21,1.79 1.168 1.090,1.252
Menb Events / At risk 1131 1132 1132 1131
First CV Event 1936 1.33 1.62 1.60 1.84 1.58,2.13 1.238 1.176,1.304
ma 1.24 1.44 1.32 1.42 1.21,1.65 1.123 1.065,1.184
All Death 1715 1.36 1.55 1.62 1.89 1.62,2.22 1.255 1.188,1.327
ma 1.25 1.35 1.29 1.39 1.18,1.64 1.116 1.055,1.180
CV Death 823 1.66 2.11 2.09 2.57 2.01,3.27 1.394 1.282,1.516
ma 1.49 1.82 1.63 1.80 1.40, 2.33 1.212 1.112,1.323
Womenb Events / At risk 1195 1192 1197 1193
First CV Event 1396 1.05 1.21 1.54 1.43 1.21,1.70 1.187 1.111,1.269
ma 0.99 1.01 1.17 1.08 0.90,1.30 1.046 0.976,1.121
All Death 1213 1.12 1.14 1.59 1.45 1.21,1.75 1.207 1.123,1.298
ma 1.05 0.98 1.20 1.13 0.93,1.37 1.067 0.991,1.149
CV Death 545 1.23 1.37 1.95 1.74 1.30,2.33 1.295 1.157,1.450
ma 1.10 1.15 1.33 1.25 0.92,1.69 1.094 0.974,1.228
Where 95% confidence limits >1.0, hazard ratios are printed bold. HRD20 is per 20-nmol/l decrease in 25OHDadj ( one standard deviation).
HRD, hazard ratio decrease; CL, confidence limits.
aAge, sex, family history of coronary heart disease, Scottish Index of Multiple Deprivation, tobacco smoking dose, total cholesterol and HDL cholesterol. BMI
did not contribute significantly to the ASSIGN score, nor did adding it in here make any difference.
bFirst fifth(1) omitted as HR¼ 1.0. For sexes combined, n¼ 2327, men n¼ 1132, women n¼ 1193. Cutpoints for centiles 80, 60, 40, 20 sexes combined are:
53.84, 42.25, 34.54, 27.12 nmol/l, respectively; men: 56.53, 45.16, 36.66, 28.92 nmol/l, respectively; women: 50.64, 39.66, 32.73, 25.79 nmol/l, respectively. For
full ranges and means see Supplement Table W3, available as Supplementary data at IJE online.
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small, with confidence intervals straddling zero (Supplement
Table W7, available as Supplementary data at IJE online).
Vitamin D, measured as 25OHDadj, appears to be a
modest, non-specific predictor of many endpoints. Its ef-
fect is largely attenuated by competing risk factors. It has
no independent effect in predicting First Cardiovascular
Events beyond that of established ASSIGN risk factors, and
would not therefore contribute significantly to cardiovas-
cular risk assessment in a multifactorial risk score.
Discussion
Neglect of the hypothesized link of seasonal sunlight to car-
diovascular disease and death is overdue for correction. It
opens a new window on the vitamin D debate. Mendelian
randomization studies7 examine fixed differences in levels.
Clinical trials raise levels, often by medication, in compliant
volunteers.3–6 Cohort studies accumulate follow-up data
(perhaps to be examined differently after this).1,2
Meanwhile a huge natural experiment, whose ‘protocol’ is
dictated by Earth’s 23.4 axis deviation and speed of angu-
lar rotation, annually raises blood levels but then lowers
them to levels research ethicists might veto. Our novel ana-
lyses and results raise questions for answering, as follows.
Baseline recruitment 25OHDraw
Serial single assays across the 13 224 participants were
used to describe the presumed monthly cycle of change
over both the years of recruitment and following decades.
Results are consistent with others, including the delays
from the solstices to peak and trough values; but, with
Scotland’s high latitude, the two-to-one oscillation may be
unusually large.12,13 Similarity of those recruited at differ-
ent times is shown by consolidated results of the two con-
trasting seasons in the Scottish districts. These show trivial
differences in mean risk factor levels, excepting an obvious
separation in mean 25OHDraw which predictably closes
with seasonal adjustment to 25OHDadj.
Seasonally adjusted 25OHDadj
As have others, we adjusted seasonally unstable 25OHDraw
readings to an estimated longer-term ranking within the
SHHEC cohort: 25OHDadj. Without adjustment, the sea-
sonal variation is extreme (see Supplement Figure 1 showing
winter and summer values, available as Supplementary data
at IJE online). The 50th centile reading for men in
January–March of 28.8 nmol/l is equal to the 6th centile in
July–September. Contrast the ‘LowD’ half of the population
of 25OHDadj coming very evenly from different recruitment
calendar months, with 25OHDraw at the same cutpoint:
52% of participants from January–March were LowD for
25OHDadj but 75% for 25OHDraw; whereas for July—
September, the figures were 50% and 20%, respectively.
Unadjusted readings are confounded by date of sampling
(also true for uncorrected clinical samples). Because the sea-
sonal swing in values is unlikely to be uniform and will vary
with the amount of sunshine in a given year and with per-
sonal exposure, 25OHDadj can only be an estimate of rank-
ing. Increased precision would necessitate multiple
measurements, and even a long-term tendency would be af-
fected by changing lifestyle, for example from inability to
venture outdoors.
Single measurements as a long-term predictor:
tracking
That 25OHD appears so unstable but nonetheless appears
predictive suggests long-term stability. Both 25OHDraw
and 25OHDadj are predictive in Cox proportional hazards
analyses. The latter is a better predictor, but the difference
is not great. External literature confirms ‘tracking’ over
time.4,29 Fortuitously, independent random sampling in
North Glasgow for MONICA surveys at 3-year intervals
sampled 35 people twice. Both 25OHDraw and 25OHDadj
values were more repeatable than other risk factors,
excluding height (see the scatter plot, Supplement Figure 2,
available as Supplementary data at IJE online). The value
of 25OHDadj as a predictor is further demonstrated in
Supplement Tables (available as Supplementary data at IJE
online). Table W8 shows that the LowD vs HighD event
ratio during follow-up appears similarly predictive whether
originally derived from Low-D season or High-D season
measurements, and Table W9 that the LowD vs HighD event
ratio persists during successive 5-year periods of follow-up.
Long-term prediction from single measurements is a
challenge to many cohort studies, not unique to 25OHD in
SHHEC. What is unusual is that the measurement is un-
stable over a period of months, but must go back on track
again despite these seasonal oscillations. Our current ana-
lyses exploit both phenomena. No other risk factor shows
such extraordinary two-to-one seasonal variation.
Pre-analytical and laboratory processing
Serum specimens analysed for 25OHD appear robust to
handling.24 Our archived frozen specimens, kept for decades
for analysis, were run off in two batches between August
2009 and February 2012 with a 17-month gap. The two
(3511 and 9713) had similar descriptors and no evidence of
laboratory drift. By defining population halves and fifths
both separately and together, we found negligible effects on
risk calculations. Use of multivitamin tablets by SHHEC re-
cruits was uncommon (see Supplement Addendum Table
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A4, available as Supplementary data at IJE online), so the
ARCHITECT assay’s comparative lack of sensitivity to
25OHD2 was immaterial. Official laboratory lower limits
did however cut across the SHHEC cohort, with 9.9%
below the European standard of 20 nmol/l and 40.7%
below the more stringent US Food and Drug Administration
(FDA) limit of 32.5 nmol/l, higher percentages of
25OHDraw occurring in winter.11,25 Our Supplement Figure
2, the analyses themselves and listing of the centiles for the
assays in Supplement Table W10 (available as
Supplementary data at IJE online), raise no questions about
the validity of these low readings for our epidemiological
purposes. The 9.9% would involve part only of the bottom
population fifth (numbered 5 in the Cox model tables), the
reference fifth, number 1, HR 10, being the highest 20%.
Readings below laboratory limits do not necessarily imply
disease.
Missing data
The 13 224 SHHEC participants were those with serum
available in 2009 when the new assay kits arrived at the
Mainz laboratory. Recruitment in 1984–95 had numbered
18 107, a 64% response rate.21 Virtually complete data on
16 000 were sent to Helsinki for the MORGAM cohort col-
laboration in 2000. In 2007, 14 751 serum specimens were
sent to Mainz for the biomarker substudy.17–19 Sequential
losses were predominantly from non-availability of serum—
first refusal or failure of venepuncture at recruitment (dur-
ing an HIV needle scare) and later depletion in laboratory
studies. Completeness of data in the 13 224 exceeds 99%,
the exception being HDL-cholesterol at 97.3%. Record
linkage depends on a death or hospital record and cumu-
lated during follow-up to 91.2%; no link means either loss
to follow-up or continuing good health.22 The 13 224 with
25OHD measurements were comparable to the 4883 with-
out in age, sex, social deprivation, risk factors and endpoint
risk. (STROBE statement is in Supplement Table W11,
available as Supplementary data at IJE online.)
Winter morbidity and mortality, other explanations
Excess winter mortality has declined since 1981. Related
to factors other than vitamin D—home heating, influenza,
respiratory disease and social conditions—they do not ne-
cessarily exclude it.30 Short-term meteorological and air
pollution precipitants of cardiovascular disease contrib-
ute.31,32 With excess mortality in northern countries begin-
ning in December, Healy33 found the least excess among
14 European countries was in Finland; winter excess corre-
lated negatively with latitude—contrary to the seasonality
hypothesis (r¼ -0.68, P< 0.01).14,33 Data for deaths (all
ages and causes) registered by calendar month and year in
Scotland over the years 1989–2009 confirm that the winter
peak each year is in December or January, therefore pre-
ceding the SHHEC trough of 25OHD in March. The sum-
mer low trough in deaths varied from May to September34
(Supplement Table W12, available as Supplementary data
at IJE online). SHHEC data on monthly incidence of car-
diovascular events and deaths need replication from studies
elsewhere.
Conclusion
Our conventional Cox proportional hazard model analyses
show 25OHDadj to be a modest non-specific predictor of
many primary and secondary endpoints, the effect being
strongly attenuated by adjustment for risk factors in the
ASSIGN cardiovascular risk score.23 Strength and gradient
are not marked: findings could result from residual con-
founding, or alternatively from over-adjustment. It does
not improve prediction of First Cardiovascular Event over
and above ASSIGN variables, an obligatory question for
the MORGAM Biomarker and BiomarCaRE studies.17–19
Seasonality analyses show that a two-to-one annual os-
cillation in population 25OHD has no apparent impact on
incidence of First Cardiovascular Events, and follows rather
than precedes the peak in All Deaths and Cardiovascular
Deaths. Winter appears to influence fatality rather than inci-
dence. There was no disproportionate susceptibility to end-
point events in the low-vitamin-D months in those ranked
as having low vitamin D, as predicted by the concept of
hypovitaminosis D. These results were consistent with the
absence of a demonstrable 25OHD threshold both in spline
analyses and in the quasi-linear gradient of increasing risk
with declining levels in the Cox model fifths. Our 25OHD
readings were low, many below laboratory limits; but with
no visible threshold for disease in SHHEC, we cannot esti-
mate the prevalence of ‘hypovitaminosis D’ in the Scottish
population, a concept originating with rickets and osteomal-
acia. Others may do so.13,14
In this study, 25OHD failed two out of three of our pos-
tulate testings and was borderline for the third. Bradford
Hill criteria for causality were found wanting for specificity,
temporality, strength and gradient.16 Although not exclud-
ing causation completely—there could be a modest delayed
effect integrated over years—our results question the sea-
sonal hypothesis of vitamin D, and therefore challenge its
alleged causal role. They need replication in other studies.
Supplementary data
Further tables and figures are available as specified in the text. The
Supplement also includes an addendum of descriptive epidemiology of
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25OHD in SHHEC covering means by age and sex (Table A1), by
year of recruitment (Table A2), in relation to lifestyle factors (Table
A3) and diet habits from a food frequency questionnaire (Table A4).
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There is little doubt that vitamin D deficiency causes rick-
ets and the physiological roles of vitamin D are wide-
spread. However, though low vitamin D status has been
associated with many other chronic diseases including car-
diovascular diseases, respiratory diseases and cancers,
whether such associations are causal is still debated.1
Skin manufacture in the presence of sunlight is the major
source of vitamin D, and the hypothesis that the marked
seasonal variations in cardiovascular diseases could be ex-
plained by seasonal variations in vitamin D status was first
proposed by Robert Scragg.2 He further reported, in a case
control study, an inverse association between plasma 25-
hydroxyvitamin D3 levels and myocardial infarction.
3
The Scottish Heart Health Extended Cohort (SHHEC),
which comprises the Scottish Heart Health study and
participants in several MONICA surveys between 1984 and
1995, aimed to examine three postulates relating to vitamin
D and cardiovascular disease (CVD), using two different
study designs.4 Their main focus was on the seasonality hy-
pothesis which they explored by using an ecological
approach. They postulated that the occurrence of cardiovas-
cular events enumerated by month of occurrence over the
years of follow-up should mirror annual seasonal oscillation
in serum 25-hydroxyvitamin D (25OHD), using monthly
means of the 25OHD concentrations observed at baseline in
the cohort. Their conclusion using this approach was that
the seasonal highs and lows in CVD deaths occurred before
the estimated seasonal peaks and troughs in 25OHD status
observed in the baseline measurements, and that first CVD
events showed no seasonal pattern. They also reported that
there was no evidence that there was greater seasonal vari-
ability in cardiovascular disease occurrence among those
with lower compared with higher 25OHD concentrations,
their second postulate. Then, in a prospective analysis of the
cohort, they reported significant associations between lower
25OHD concentrations at baseline with subsequent first
CVD events, CVD deaths and all deaths, before and after
multiple adjustments for other factors.
The authors’ conclusions were: that 25OHD failed two
out of three of their postulated testings and was borderline
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